Loading
A gene test on a prostate biopsy that estimates how aggressive the cancer is, to help decide between active surveillance and treatment.
Prolaris (Myriad Genetics) measures how fast tumour cells are dividing and reports a 10-year risk of dying from prostate cancer under conservative management and of metastasis after treatment. It is listed in NCCN guidelines as an option for men with low or favourable-intermediate risk disease considering active surveillance, is covered by Medicare, and validated in conservatively managed UK cohorts and US surgical series. Like Decipher and Oncotype DX GPS it refines, rather than replaces, PSA, Gleason grade and MRI; head-to-head comparisons are few and none of the three has randomised evidence that its use improves outcomes.
RT-PCR of 31 cell-cycle progression genes and 15 housekeeping genes on biopsy tissue, combined with clinical risk (CAPRA) to estimate 10-year prostate cancer mortality and metastasis risk.
1.Prolaris slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Prolaris" OR ABSTRACT:"Prolaris") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Prolaris, not a curated reading list.
Shares Myriad Genetics, RNA sequencing & expression profiling and the tag test.
Shares Myriad Genetics, Prostate cancer and the tag test.
Shares Myriad Genetics and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares Prostate cancer and the tag test.